Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by issuing an additional 1 billion unissued shares, subject to approval at a special shareholders' meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 560 million to 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million, assuming no changes in the number of shares issued prior to the record date [2] Group 2 - The company intends to use the net proceeds from the rights issue for several purposes, including the development of existing pharmaceutical wholesale and distribution businesses, as well as dialysis treatment and consulting services [2] - Part of the proceeds will be allocated to settle trade and other payables of approximately HKD 5 million and to repay a director's loan and accrued interest of approximately HKD 8.5 million [2] - The remaining funds will be utilized for general working capital, which includes but is not limited to salaries, rent expenses, professional fees, and other corporate expenses [2]
万嘉集团(00401)拟增加法定股本及按“1供1”基准进行供股